Abstract
Multiple myeloma (MM) comprises 1% of all malignancies and 13% of hematological malignancies in the Caucasian population. Yearly incidence is 4/100,000 in the US and is higher in blacks and males [1]. The pathogenesis of the disease is relatively unknown; several chromosomal abnormalities have been related to the development of the disease,but none is characteristic of MM. Cyclin-D1 is a protein encoded by the CCND1 (bcl-1) gene on chromosome 11q13, and is an important regulator of G1 to S phase progression.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers / metabolism
-
Bone Marrow / metabolism*
-
Bone Marrow / pathology
-
Cohort Studies
-
Cyclin D1 / genetics
-
Cyclin D1 / metabolism*
-
Female
-
Follow-Up Studies
-
Greece
-
Humans
-
Male
-
Middle Aged
-
Multiple Myeloma / diagnosis
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / metabolism*
-
Multiple Myeloma / pathology
-
Neoplasm Staging
-
Prognosis
-
RNA, Messenger / metabolism
-
Survival Analysis
-
Up-Regulation / drug effects*
Substances
-
Biomarkers
-
CCND1 protein, human
-
RNA, Messenger
-
Cyclin D1